Information Provided By: 
Fly News Breaks for August 3, 2016
PRTA
Aug 3, 2016 | 14:03 EDT
Ladenburg Thalmann analyst Robert Hazlett said the recently released clinical data from the Phase 1/2 study of NEOD001 continue to point to promising organ responses that do not appear to be related to prior plasma cell directed therapy. Noting there are catalysts upcoming for NEOD001, PRX002 and PRX003, the analyst raised his price target on the stock to $80, adding that he assigns a 70% probability of Prothena operating independently and a 30% probability to a takeover.
News For PRTA From the Last 2 Days
There are no results for your query PRTA
